Alzheimer’s disease is a condition that slowly affects memory and thinking. It is the most common cause of dementia and mainly affects older adults.
People often believe that once Alzheimer’s begins, everyone follows a similar path, with memory and thinking getting worse at a steady rate. However, new research suggests that this is not true.
A study from the Keck School of Medicine at the University of Southern California found that people in the early stage of Alzheimer’s can follow very different paths.
The research was published in the journal Alzheimer’s & Dementia. Scientists followed a group of people for about six years. These people did not show symptoms at the beginning, but some had early signs in their brains that Alzheimer’s might develop.
The researchers discovered three main patterns. Some people stayed stable and showed little or no decline. Others declined slowly over time. A smaller group declined much faster. Surprisingly, about 70 percent of participants stayed stable during the study period. This shows that Alzheimer’s is not the same for everyone.
To understand why these differences happen, the scientists looked at biological signs in the body. These included blood tests and brain scans.
One important marker was a protein called P-tau217, which is linked to Alzheimer’s. People with higher levels of this protein were more likely to experience faster decline. They also had smaller hippocampus sizes, a brain area important for memory.
The researchers were able to use this information to predict who might decline faster, with about 70 percent accuracy. While this is not perfect, it is a big step forward. It suggests that doctors may one day be able to give patients a clearer idea of what to expect.
This study also raises important questions about how clinical trials are done. Many trials assume that all patients decline at the same rate. But if most people remain stable for years, it becomes hard to tell if a new treatment is working. The study suggests that future trials should focus more on individuals who are likely to decline.
Overall, this research shows that Alzheimer’s disease is more complex than once thought. It highlights the need for more personalized approaches in both care and research.
While the findings are promising, more work is needed to improve prediction and understand why some people stay stable. This could lead to better treatments and possibly ways to slow or prevent the disease.
If you care about Alzheimer’s disease, please read studies about vitamin D deficiency linked to Alzheimer’s and dementia, and strawberries can be good defence against Alzheimer’s.
For more health information, please see recent studies about foods that reduce Alzheimer’s risk, and oral cannabis extract may help reduce Alzheimer’s symptoms.
